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SUPPRESSION OF ACUTE AND CHRONIC 
INFLAMMATION BY ORALLY ADMINISTERED 
PROSTAGLANDINS 
STEVEN L. KUNKEL, HIROSHI OGAWA, PHILIP B. CONRAN, PETER A. WARD, and 
ROBERT B. ZURIER 
Oral administration of a stable analog of prosta- 
glandin El (PGE,), 15-(S)-15-methyl-prostaglandin El, 
can suppress both chronic adjuvant-induced polyarthri- 
tis and acute immune complex-induced vasculitis in a 
dose dependent manner. Histopathologic studies of 
tibiotarsal joints from rats with adjuvant disease showed 
suppression of arthritis in animals treated with the 
PGE, analog from time of adjuvant challenge. This 
study represents the first demonstration of suppressed 
experimental polyarthritis by an orally administered 
prostaglandin. Suppression of the acute immune com- 
plex-induced vasculitis was demonstrated using 15- 
methyl-PGE, administered orally 12 hours prior to 
antigen-antibody challenge. Diminution of tissue injury 
resulting from immune complex-induced vasculitis is re- 
flected by a decrease in vaso-permeability, indicating 
suppressed vascular damage in animals treated with 
prostaglandin. These studies demonstrate the potential 
use of orally active prostaglandins as an antiinflamma- 
tory agent. 
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It is becoming increasingly evident that prosta- 
glandins (PG) play an integral role in regulating the 
functions of cells involved in immune and inflamma- 
tory reactions (1). Clearly not only are PG produced by 
inflammatory cells and able to influence the outcome of 
inflammation (2), but they can also suppress diverse ef- 
fector systems in inflammatory reactions. Thus, PGE 
compounds, which increase levels of cyclic AMP in leu- 
kocytes, reduce chemotactic responses of polymorpho- 
nuclear leukocytes (PMN) (3), reduce selective ex- 
trusion of IysosomaI enzymes from PMN (4), prevent 
IgE-induced histamine release from lung fragments and 
basophils (5), and inhibit lymphocyte mediated cyto- 
toxicity (6). Pharmacologic doses of PGE, and PGE, 
administered subcutaneously suppress both acute and 
chronic inflammation in several experimental models 
(7). Furthermore, PGE have been shown to modulate 
the effects of vasoactive compounds (8), which are re- 
sponsible for many early changes in both acute and 
chronic immune reactions. 
Prostaglandin E compounds appear to have a 
regulatory effect on the character and intensity of im- 
mune responses in vivo (9). Long-term administration 
of PGE, has proved feasible and has been shown to 
markedly prolong survival of NZB/NZW (lupus) mice, 
even when treatment is begun after nephritis has devel- 
oped (10). However, under these conditions, the dose of 
PGE, required is substantial (200 pg subcutaneously, 
twice daily). A derivative of PGE,-l5-(S)-15-methyl 
PGE,( 1 5-M-PGEIehas been developed and is more 
resistant than PGE, to the activity of 1 S-hydroxy-pros- 
taglandin dehydrogenase (1  1). Previously, we have re- 
ported (12) that a very small dose of I5-M-PGEI (4 pg 
given subcutaneously, twice daily) prolongs survival of 
NZB/NZW mice in which there is established disease 
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at the time treatment is begun. In addition, we have re- 
ported ( 13) that immune complex-induced vascular 
damage can be markedly suppressed by treatment of 
rats with l5-M-PGEI. 
We now show that oral administration of 15-M- 
PGE, in a dose dependent manner suppresses acute im- 
mune complex-induced vasculitis and adjuvant-in- 
duced chronic polyarthritis in rats. The reversed passive 
Arthus reaction (RPA) is induced by the intravenous 
administration of antigen and the local (intradermal) in- 
jection of antibody and is a good model for immunolog- 
ically induced acute vasculitis. Adjuvant arthritis ap- 
pears in rats 10-14 days after a single intradermal 
injection of Freund’s complete adjuvant and is a good 
model for chronic inflammation that is dependent on 
cell mediated immunity; thus, adjuvant arthritis pro- 
vides a convenient experimental model for in vivo eval- 
uation of antiinflammatory and/or immunosuppressive 
agents (14). This work to be reported here represents 
one of the first efforts to regulate both acute and chronic 
inflammatory reactions in animal models by oral treat- 
ment with PG. 
MATERIALS AND METHODS 
Animals. Adult male Lewis rats (Charles River Breed- 
ing Laboratories, Wilmington, MA) weighing 200-250 gm 
were used throughout these studies. 
Adjuvant-induced chronic arthritis. Polyarthritis was 
induced in the Lewis rat by the intradermal injection of 500 
p g  heat-killed Mycobocferiurn tuberculosis organisms (Difco 
Laboratories, Detroit, MI) in 0.1 ml of mineral oil into the left 
hind paw. Adjuvant-induced arthritis appeared in all positive 
control rats at approximately day 14. The severity of the poly- 
arthritis was evaluated in the 3 uninjected paws by using both 
an arbitrary point system and direct measurement with a cali- 
per. The uninjected paws were scored in the following man- 
ner: 1 point was assigned for each of the inflamed tibiotarsal 
joints, 5 points for each of the inflamed tarsal joints, and 5 
points for arthritic involvement of the tail. Each of 4 groups 
containing 10 rats each were injected with the M tuberculosis 
in oil and were separated into Group 1, which received 200 p g  
of IS-M-PGE, once daily from the day of adjuvant challenge; 
Group 2, which received 100 pg of 15-M-PGE, by mouth 
from the day of adjuvant injection; Group 3, which received 
50 pg of lS-M-PGE, once daily again from the time of adju- 
vant injection; and Group 4, which was given 0.5 ml of fluid. 
All of the above experiments were conducted in triplicate on 
three different occasions. The progress of the polyarthritic 
joint disease was also followed in the noninjected paws by 
measuring each of the joints with a caliper at 2-day intervals. 
Immune complex-induced acute vasculitis. The re- 
versed passive Arthus reaction using rabbit IgG antibody to 
bovine serum albumin (BSA) was used as the antibody to 
elicit the immune complex vasculitis, as previously described 
(15). Approximately 150 p1 of anti-BSA IgG containing 150 pg 
N antibody was injected intradermally, followed by the intra- 
venous injection of 10 mg BSA and I pCi of I2’I rat serum al- 
bumin. The radiolabeled rat serum albumin served as a per- 
meability marker and as an index for the degree of vascular 
damage (16). Negative control sites were injected with saline 
or antibody from which the intravenous injection of antigen 
was omitted. Three hours after antigen-antibody challenge, 
the animals were killed. At the site of each intradermal injec- 
tion, a circular punch of skin 1 cm in diameter was excised. In 
addition, 1 ml of blood was removed from the left ventricle of 
the heart; both skin and blood samples were measured for 
gamma emissions. The ratio of radioactivity in each skin site/ 
1 ml of blood was computed and used as the permeability in- 
dex. 
Prostaglandins. Prostaglandins were a gift of Dr. John 
E. Pike, Upjohn Co., Kalamazoo, Michigan. Stock solutions 
of PG12, lS-M-PGE,, and 16,16 dimethyl PGE, were pre- 
pared in absolute ethanol and diluted to 10 mg/ml in sterile 
phosphate buffered saline (PBS), pH 7.2. Prior to use, the PG 
were diluted to the desired concentration with PBS. 
Morphologic analysis. Skin samples from the various 
inflammatory and control sites were fixed in phosphate buf- 
fered @H 7.0) 10% formaldehyde and were then prepared for 
routine light microscopy. After killing the animals with ether 
anesthesia, the legs of all those challenged with the Myco- 
bacterium in mineral oil were removed and k e d  in buffered 
10%0 formaldehyde and then decalcified with acetic acid. Sec- 
tions of each fixed and decalcified tibiotarsal joint were 
stained with hematoxylin and eosin. 
Statistical analysis. The unpaired Student’s f-test was 
used to analyze the data. 
RESULTS 
Suppression of polyarthritis by oral prostaglan- 
din treatment. A severe polyarthritic response was 
grossly visible in all non-PG treated control rats. Using 
oral treatment with 15-M-PGE,, a dose dependent ame- 
lioration of the polyarthritis was observed. Little or no 
gross change was observed in the joints of animals given 
200 pg of the 15-M-PGEl daily from the time of adju- 
vant administration. The oral administration of 100 pg 
and 50 pg of 15-M-PGE, resulted in a significant gross 
attenuation of the polyarthritis as compared to the con- 
trol animals. Prostaglandin treatment of rats with 200 
pg l5-M-PGEI led to diarrhea and somnolence which 
lasted approximately 1 hour, while the lower doses pro- 
duced only transient diarrhea and the animals remained 
active. 
As shown in Figure 1, oral administration of 15- 
M-PGE, markedly suppressed the polyarthritic re- 
sponse in a dose-dependent manner. The oral ad- 
ministration of 200 pg 15-M-PGE, resulted in a 90% 
reduction in the mean arthritic score of the joints in the 
non-adjuvant treated paws by day 20. It is interesting to 
note that not only was the degree of swelling of the soft 
tissue around the joints markedly diminished in the ani- 
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Figure 1. Effect of orally administered 15-(S)-15-methyl-prostaglan- 
din El on adjuvant polyarthritis. C--. = positive test; [T-u = 
15-M-PGEI. Each point represents the mean arthritic score for the 3 
uninjected paws (10 rats per group treated from the day of adjuvant 
challenge). Error bars represent f standard error of the mean. 
50 pg 15-M-PGEI; &-A = 100 pg 15-M-PGEI; M =. 200 pg 
mals receiving this dose of 15-M-PGEl, but there was 
also a significant delay in the onset of disease. 
Although not as dramatic as with the higher 
dose, the daily oral administration of 100 pg and 50 pg 
of 15-M-PGE, suppressed the polyarthritis by 500/0 and 
20%, respectively (Figure 1). In both PG treated and 
nontreated animals, the peak arthritic response oc- 
curred at approximately day 21. As compared to non- 
treated rats, the mean paw thickness in all the 15-M- 
PGE, treated animals was significantly reduced, in- 
dicative of a suppression of soft tissue swelling in each 
of the joints. As shown in Table 1, the mean paw thick- 
ness measured at day 20 following adjuvant injection 
was suppressed in a dose-dependent manner. There was 
little statistical difference between the mean paw thick- 
ness in the 200 pg 15-M-PGE, treated animals (injected 
with adjuvant) and normal (non-adjuvant treated) con- 
trol animals. Although not as dramatic as with the 200 
pg dose, the oral administration of 100 pg and 50 pg at- 
tenuated the joint swelling in each of the noninjected 
paws. It is also of interest that the swelling of soft tissue 
in the adjuvant-injected left hind paw was suppressed in 
a dose-dependent fashion. 
Histology of tibiotarsal joints from treated and 
untreated rats 20 days after adjuvant injection was com- 
pared with joints from normal rats. A histologic section 
from a joint of an animal with polyarthritis is shown in 
Figure 2. The histologic changes evident in polyarthritic 
rats demonstrated significant encroachment of the joint 
space by an inflamed synovium and advancement of 
pannus to the center of the cartilage. The inflammatory 
response associated with erosion of articular cartilage 
was characteristic of fully developed adjuvant arthritis 
(Figure 2). Arthritis failed to develop in joints of rats 
treated (from day 1) with 200 pg of 15-M-PGEI; histo- 
logically, these joints appeared normal. Joints from ani- 
mals treated with 100 pg 15-M-PGEl demonstrated ex- 
tension of pannus only over the periphery of cartilage. 
Also, invasion of cartilage and bone by pannus was seen 
in joints of animals treated with 50 pg/day 15-M-PGEl, 
but the joint space was preserved (Figure 3), demon- 
strating the dose response of PGE treatment. These re- 
sults indicate that the arthritic reaction in animals 
treated orally with 15-M-PGEl are either attenuated 
(100 or 50 pg) or totally suppressed (200 pg) in a manner 
that is dose-dependent. 
Suppression of acute vasculitis. Oral administra- 
tion of 15-M-PGE, suppressed acute immune complex- 
induced vasculitis in a dose-dependent manner (Figure 
4). In this particular study, animals were treated 12 
hours previously with the 15-M-PGEl and then injected 
with antigen and antibody. Changes in the vascular per- 
meability indicative of the intensity of the inflammatory 
reaction and tissue injury were always related to values 
found in saline injected sites. Animals serving as posi- 
tive controls received the intradermal injections of anti- 
body and intravenous injection of BSA plus labeled rat 
albumin, but they were not treated with PG. For each 
Table 1. Effect of orally administered 15-(S)-15-methyl prostaglandin El on soft tissue swelling in 
polyarthritic rats. Each number represents the mean paw thickness for either the uninjected paws or the 1 
injected paw. (Ten rats per group were treated from day of adjuvant challenge) 
Mean paw thickness (cm) 20 days post-challenge 
Hind left 
right paw left paw right paw injected 
Front Front Hind paw, adjuvant 
Positive test 0.61 f 0.04 0.56 k 0.02 0.64 f 0.02 1.32 f 0.06 
50pg 15-M-PGE) 0.52 f 0.02 0.48 f 0.01 0.50 f 0.04 1.22 f 0.03 
1OOpg 15-M-PGEI 0.49 f 0.02 0.43 f 0.02 0.47 f 0.03 1.16f0.06 
0.40 f 0.01 0.44 f 0.03 0.90 f 0.05 -~ 2OOpg 15-M-PGEI 0.38 f 0.05 
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Figure 2. Joint from untreated rat at day 20. lnvasive pannus encroaching upon the cartilage and the bone (he- 
matoxylin and eosin; magnification x 100). 
Figure 3. Joint from rats at day 20 treated orally with 50 pg 15-(S)-15-methyl-prostaglandin El from day of ad- 
juvant challenge. Synovia extends over the cartilage and bone, but the pannus has not encroached upon the 
joint space. Some fibrinous exudate is free in the joint space (hematoxylin and eosin; magnification X 100). 
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Figure 4, Effect of orally administered 15-(S)-15-methyl prostaglan- 
din El on immune complex-induced vasculitis. Animals were treated 
12 hours prior to antigen-antibody challenge. The vascular per- 
meability was computed as in Materials and Methods and expressed 
as experimental/control. The P value for the doses of 75 pg, 125 pg, 
and 250 pg was < 0.01 and for 50 pg the P value was < 0.1, as com- 
pared to the positive test group. 
of the experiments, 6 animals were given 4 intradermal 
injections of saline (negative controls) and 4 intra- 
dermal injections of antibody (positive test). Thus, each 
animal contained both negative and positive test sites. 
Also there was no statistical difference in s a h e  sites 
fom PG treated and nontreated animals. The 15-M- 
5 i POS. 
Figure 5. Effect of subcutaneously administered PGIl on immune 
complex-induced vasculitis. The vascular permeability was computed 
as in Materials and Methods and expressed as experimental/controI. 
The P value for the 500 pg dose was < 0.01,250 pg dose < 0.1, and the 
125 pg dose < 0.2. 
PGE, treatment of rats resulted in suppression of vascu- 
lar damage ranging from approximately 10% at the dose 
of 50 pg 15-M-PGEl to 75% suppression with the 250 pg 
dose (Figure 4). 
In an attempt to determine whether the long last- 
ing suppression of immune compIex vasculitis could 
only be induced by treatment with the 15-methyl deriv- 
ative of PGE,, both PGI,, and a PGE, analog with a 
dimethyl at the 16 position were also studied. Oral ad- 
ministration of either PGI,, PGE,, or 16,16 dimethyl 
PGE, did not suppress acute vasculitis. However, since 
subcutaneous injections of PGE, suppress immune 
complex vasculitis (13), animals were treated subcuta- 
neously with either PGI, or 16,16 dimethyl PGE,, rested 
for 1 hour, and then challenged with antigen and anti- 
body. The largest dose of the administered PGI, (500 
pg) resulted in a reduction of vascular permeability by 
approximately 50%, while 250 pg PGI, caused a diminu- 
tion of the vascular leakage by 10% (Figure 5). The 
treatment of animals with 500 pg 16,16 dimethyl PGE,, 
in the manner as described for PGI,, resulted in a sup- 
pression of the vascular leakage by 6Wo. When 250 pg 
of this PGE, analog was examined, the permeability 
was reduced by 35% (Figure 6). 
In all positive control reactions, the skin lesions 
were shown to have extensive deposition of both BSA 
and C3 in walls of dermal venules and capillaries, as de- 
termined by immunofluorescence. In rats treated with 
15-M-PGEi, the deposition of BSA and C3 were con- 
fined mainly to the immediately adjacent perivascular 
tissue. Thus, it appeared that PG treatment did not 
block complement fixation or deposition of immune 
Flgure 6. Effects of subcutan~usly administered 16.16 dimethyl 
prostaglandin El on immune complex-induced vasculitis. The P 
value for the 500 g dose was <0.001,25 pg t0.01, and 125 pg i 0.2. 
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complexes. When vascular damage was suppressed by 
the prostaglandin treatment, skin reactions were visibly 
inhibited, with little induration, edema, or erythema. 
Histologically, the nontreated positive sites showed the 
expected diffuse intraluminal, perivascular infiltrates of 
polymorphonuclear leukocytes (Figure 6A). In contrast, 
lesions from rats treated with a suppressive dose of ei- 
ther PG showed a diminished infiltrate of neutrophils 
(Figure 6B). The histology of the PG-suppressed lesions 
appeared similar, and the intensity of the reactions was 
dose-dependent. 
DISCUSSION 
The data presented in this paper indicate that 
oral administration of a stable derivative of PGE,, 
15(S)- 15-methyl PGE,, produces potent suppression of 
acute immune complex-induced inflammatory reac- 
tions, as well as suppression of the more delayed and 
chronic inflammatory response in adjuvant arthritis. 
The suppressive effect of oral 15-M-PGEl treatment ap- 
pears to be partially specific since no inhlbition of the 
inflammatory response occurred with oral administra- 
tion of 16,16 dimethyl PGE, or PGI,. This reflects both 
the enzymatic and spontaneous degradation of these 
two compounds, especially PGI,. The ability to inhibit 
the arthritic response by oral treatment of therapeutic 
levels of 15-M-PGEl probably lies in the molecular 
structure of the analog, which is not susceptible to the 
15-hydroxy-prostaglandin dehydrogenase (1 1). The ac- 
tivity of this enzyme is probably the reason why signifi- 
cant doses of the classic prostaglandins are required to 
achieve physiologic effects (17). 
The pathogenesis of the Arthus reaction may not 
be dissimilar from the series of events thought to be re- 
sponsible for joint tissue damage in rheumatoid arthritis 
(RA): formation of immune complexes in vessel walls, 
activation of complement and local generation of chem- 
otactic peptides derived from the fifth component of 
complement, influx of polymorphonuclear leukocytes in 
A B 
Figure 7. Acute immune complex-induced vasculities in A, prostaglandin treated and B, nontreated animals. The nontreated 
animals show an intraluminal infiltrate of neutrophils, while the infiltrate in the treated animals was significantly diminished. 
As stated in the text, the histology of the prostaglandin suppressed lesions appeared similar and the intensity of the reactions 
was dose-dependent. 
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response to chemotactic products, endocytosis of im- 
mune complexes, and subsequent release of lysosomal 
enzymes and other mediators of inflammation resulting 
in vascular damage (1 8). Previous investigations have 
shown that treatment of rats with ISM-PGE, can mod- 
ulate many of the above steps in the acute inflammatory 
response, especially the direct motion and degranula- 
tion of peripheral blood neutrophils (13). 
The ability of both the classic prostaglandin E, 
and prostacyclin to inhibit immune complex-induced 
vasculitis may be due to the interaction of these par- 
ticular prostaglandins with identical receptors on the 
neutrophil surface. Previous investigators (19) have pro- 
posed that prostaglandins of the E series and pro- 
stacyclin bind to similar granulocyte receptors to induce 
an increase in intracellular cyclic AMP levels, thus lead- 
ing to an attenuation of inflammatory responses. The 
ability of PGE, and PGI, to bind identical receptors 
and inhibit adenosine diphosphate-induced aggregation 
of platelets in a number of species has also been estab- 
lished (20). Therefore the effects of PGE, and PGI, on 
neutrophil dependent, immune complex-induced vas- 
culitis may add credence to the identical binding theory 
of these two prostaglandins. 
Whereas acute immune complex-induced vascu- 
litis is characterized by neutrophil infiltration, tissue 
proliferation is the hallmark of chronic inflammation. 
Therefore, appropriate control of cell proliferation is 
crucial to improved management of a disease like RA, 
for example, in which synovium develops into granula- 
tion tissue (pannus) that invades and erodes articular 
cartilage. Intracellular degradation of newly synthesized 
collagen in vitro is inhibited by PGE (21), and this ac- 
tion may aid in the control of collagen deposition in 
chronic inflammatory disorders. 
The role of prostaglandins in immunologic re- 
sponses and inflammatory reactions is complex, but 
these ubiquitous compounds do appear important in the 
regulation of cell function and host defenses. Studies 
such as those presented here do not necessarily argue 
for a physiologic role for prostaglandins. They do sug- 
gest that pharmacologic doses of prostaglandins, even 
when given by mouth, may be capable of influencing 
some aspects of immunity and inflammation and can 
prevent tissue injury. That PGE can inhibit the dermal 
Arthus reaction makes it not unreasonable to consider 
its use in treatment of cutaneous vasculitis not con- 
trolled by more traditional therapy. 
The therapeutic potential of the prostaglandins 
appears great, and their use for a wide variety of dis- 
eases is just beginning. Whether they will prove helpful 
clinically as modulators of immune/inflammatory re- 
sponses is not yet clear. 
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